Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–16.

Article  CAS  PubMed  Google Scholar 

Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.

Article  PubMed  Google Scholar 

Huang JT, Zhong BY, Jiang N, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors plus tyrosine kinase inhibitors versus immune checkpoint inhibitors plus tyrosine kinase inhibitors for advanced hepatocellular carcinoma. J Hepatocell Carcinoma. 2022;9:1217–28.

Article  PubMed  PubMed Central  Google Scholar 

Yang F, Yang J, Xiang W, et al. Safety and efficacy of transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for hepatocellular carcinoma. Front Oncol. 2021;11: 657512.

Article  CAS  PubMed  Google Scholar 

El-Khoueiry AB, Llovet JM, Vogel A, et al. LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2022;40(4):TPS494-94.

Article  Google Scholar 

Zhu HD, Li HL, Huang MS, et al. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8:58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197–18.

Article  CAS  PubMed  Google Scholar 

Schobert IT, Savic LJ, Chapiro J, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. Eur Radiol. 2020;30:5663–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mocan T, Ilies M, Nenu I, et al. Serum levels of soluble programmed death-ligand 1 (sPD-L1): a possible biomarker in predicting post-treatment outcomes in patients with early hepatocellular carcinoma. Int Immunopharmacol. 2021;94: 107467.

Article  CAS  PubMed  Google Scholar 

Zhou G, Sprengers D, Boor PPC, et al. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas. Gastroenterology. 2017;153:1107-19e10.

Article  CAS  PubMed  Google Scholar 

Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75:2139–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Craciun L, de Wind R, Demetter P, et al. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer. 2020;20:135.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montasser A, Beaufrere A, Cauchy F, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology. 2021;79:36–46.

Article  PubMed  Google Scholar 

Pinato DJ, Murray SM, Forner A, et al. Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy. J Immunother Cancer. 2021;9(9):e003311.

Article  PubMed  PubMed Central  Google Scholar 

Tischfield DJ, Gurevich A, Johnson O, et al. Transarterial embolization modulates the immune response within target and nontarget hepatocellular carcinomas in a rat model. Radiology. 2022;303:215–25.

Article  PubMed  Google Scholar 

Ueshima E, Sofue K, Takaki H, et al. Lenvatinib mitigates transarterial embolization-induced polarization of tumor-associated macrophages in a rat hepatocellular carcinoma model. J Vasc Interv Radiol. 2023;34(1977–85): e4.

Google Scholar 

Buijs M, Geschwind JF, Syed LH, et al. Spontaneous tumor regression in a syngeneic rat model of liver cancer: implications for survival studies. J Vasc Interv Radiol. 2012;23:1685–91.

Article  PubMed  PubMed Central  Google Scholar 

Pinter M, Jain RK, Duda DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: a review. JAMA Oncol. 2021;7:113–23.

Article  PubMed  PubMed Central  Google Scholar 

Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol. 2019;70:999–07.

Article  PubMed  PubMed Central  Google Scholar 

Xue TC, Jia QA, Ge NL, Chen Y, Zhang BH, Ye SL. Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma. Tumour Biol. 2015;36:8797–03.

Article  CAS  PubMed  Google Scholar 

Tan J, Fan W, Liu T, et al. TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol. 2023;79:126–40.

Article  CAS  PubMed  Google Scholar 

Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III. Randomized Clinical Trial (LAUNCH). 2023;41:117–27.

CAS  Google Scholar 

Takaki H, Hirata Y, Ueshima E, et al. Hepatic artery embolization enhances expression of programmed cell death 1 ligand 1 in an orthotopic rat hepatocellular carcinoma model in vivo and in vitro experimentation. J Vasc Interv Radiol. 2020;31(9):1475–82.

Article  PubMed  Google Scholar 

Miyayama S, Matsui O, Zen Y, et al. Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: observation on CT during arterial portography. Hepatol Res. 2011;41:853–66.

Article  PubMed  Google Scholar 

Lencioni R, Kudo M, Erinjeri J, et al. 2024. EMERALD-1 A phase 3 randomized placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. 42: LBA432

Kudo M. Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma. Liver Cancer. 2018;7:1–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kudo M. Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma. Liver Cancer. 2020;9:629–39.

Article  PubMed  PubMed Central  Google Scholar 

Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity. 2023;56:2188–205.

Article  CAS  PubMed  Google Scholar 

Shi F, Shi M, Zeng Z, et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer. 2011;128:887–96.

Article  CAS  PubMed  Google Scholar 

Doedens AL, Phan AT, Stradner MH, et al. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol. 2013;14:1173–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vuillefroy de Silly R, Ducimetiere L, Yacoub Maroun C, Dietrich PY, Derouazi M, Walker PR. Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells. Eur J Immunol. 2015;45:2263–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gropper Y, Feferman T, Shalit T, Salame TM, Porat Z, Shakhar G. Culturing CTLs under hypoxic conditions enhances their cytolysis and improves their anti-tumor function. Cell Rep. 2017;20:2547–55.

Article